D
Daniel C. Aronson
Researcher at Boston Children's Hospital
Publications - 108
Citations - 5255
Daniel C. Aronson is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Hepatoblastoma & Quality of life. The author has an hindex of 41, co-authored 103 publications receiving 4664 citations. Previous affiliations of Daniel C. Aronson include VU University Amsterdam & VU University Medical Center.
Papers
More filters
Journal ArticleDOI
2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group
Derek J. Roebuck,Daniel C. Aronson,Philippe Clapuyt,Piotr Czauderna,Jean de Ville de Goyet,Frédéric Gauthier,Gordon A. MacKinlay,Rudolf Maibach,Kieran McHugh,Øystein E. Olsen,Jean-Bernard Otte,Danièle Pariente,Jack Plaschkes,Margaret Childs,Giorgio Perilongo +14 more
TL;DR: This paper, written by members of the radiology and surgery committees of the International Childhood Liver Tumor Strategy Group (SIOPEL), presents various clarifications and revisions to the original PRETEXT system.
Journal ArticleDOI
Successful Treatment of Childhood High-Risk Hepatoblastoma With Dose-Intensive Multiagent Chemotherapy and Surgery: Final Results of the SIOPEL-3HR Study
Jozsef Zsiros,Rudolf Maibach,E. Shafford,Laurence Brugières,Penelope Brock,Piotr Czauderna,Derek J. Roebuck,Margaret Childs,Arthur Zimmermann,Véronique Laithier,Jean-Bernard Otte,Beatriz de Camargo,Gordon A. MacKinlay,Marcelo Scopinaro,Daniel C. Aronson,Jack Plaschkes,Giorgio Perilongo +16 more
TL;DR: The applied treatment rendered a great proportion of tumors resectable, and, in comparison with previously published results, led to an improved survival in patients with high-risk hepatoblastoma.
Journal ArticleDOI
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma
Giorgio Perilongo,Rudolf Maibach,Elisabeth Shafford,Laurence Brugières,Penelope Brock,Bruce Morland,Beatriz de Camargo,Jozsef Zsiros,Derek J. Roebuck,Arthur Zimmermann,Daniel C. Aronson,Margaret Childs,Eva Widing,Véronique Laithier,Jack Plaschkes,Jon Pritchard,Marcello Scopinaro,Gordon A. MacKinlay,Piotr Czauderna +18 more
TL;DR: Cisplatin monotherapy achieved similar rates of complete resection and survival among children with standard-risk hepatoblastoma and doxorubicin can be safely omitted from the treatment of standard- risk hepatoblowlastoma.
Journal ArticleDOI
Management of trichobezoar: case report and literature review
Ramon R. Gorter,C. M. F. Kneepkens,E. C. J. L. Mattens,Daniel C. Aronson,Daniel C. Aronson,Hugo A. Heij +5 more
TL;DR: According to the experience and in line with the published results, conventional laparotomy is still the treatment of choice and psychiatric consultation is necessary to prevent relapses.
Journal ArticleDOI
Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study
Jozsef Zsiros,Laurence Brugières,Penelope Brock,Derek J. Roebuck,Rudolf Maibach,Arthur Zimmermann,Margaret Childs,Danièle Pariente,Véronique Laithier,Jean-Bernard Otte,Sophie Branchereau,Daniel C. Aronson,Arun Rangaswami,Milind Ronghe,Michela Casanova,Michael J. Sullivan,Bruce Morland,Piotr Czauderna,Giorgio Perilongo +18 more
TL;DR: The SIOPEL-4 treatment regimen is feasible and efficacious for complete remission at the end of treatment for patients with high-risk hepatoblastoma.